AIMD
vs
S&P 500
AIMD
S&P 500
Over the past 12 months, AIMD has underperformed S&P 500, delivering a return of -10% compared to the S&P 500's +14% growth.
Stocks Performance
AIMD vs S&P 500
Performance Gap
AIMD vs S&P 500
Performance By Year
AIMD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ainos Inc
Glance View
Ainos, Inc. engages in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.